Oxbryta Settlement Calculator 2026: Estimate Potential Claim Value
Use the Oxbryta Settlement Calculator to organise voxelotor prescription history, the injury alleged, treatment records, medical expenses and the evidence behind a sickle cell drug withdrawal claim.
- Organises prescription dates, dosage and duration of voxelotor treatment.
- Captures the injury alleged — stroke, organ failure, acute chest syndrome or death.
- Helps identify missing pharmacy, haematology and hospital records.
- Makes clear how early this litigation still is.
Get Your Oxbryta Claim Estimate
Answer the guided questions using the most accurate prescription, diagnosis, treatment and damages information available.
Is the calculator estimate what I would receive?
No. It is a gross figure, and no Oxbryta settlement exists to be paid from. Attorney fees, case expenses and lien repayment would all come out of any eventual allocation.
Should I wait for an MDL to be formed?
Waiting carries real risk here. The withdrawal was in September 2024, and in shorter-limitation states deadlines may be closer than claimants expect. Consolidation would change the timetable, not the deadline.
How the Oxbryta Settlement Calculator Works
The calculator organises the facts most likely to matter in an initial claim review. Because this litigation is at an early stage with no settlement matrix, its output is a structured summary rather than a prediction.
1. Record the Prescription
Enter when voxelotor was started, the dosage and how long it was taken before withdrawal or discontinuation.
2. Enter the Injury
Stroke, kidney failure, liver failure, acute chest syndrome, bone necrosis, worsened vaso-occlusive crises or death.
3. Add Treatment History
Hospital admissions, transfusions, surgery, dialysis and ongoing care following the injury.
4. Review What Is Missing
The output highlights the pharmacy, haematology and hospital records an attorney will ask for.
Factors That Can Affect Oxbryta Settlement Value
Because no settlement matrix exists, these are the factors that comparable pharmaceutical litigation suggests will drive value.
Severity of injury
Stroke, organ failure and death sit at the top of any pharmaceutical injury matrix; worsened crises without lasting damage sit lower.
Documented prescription period
Pharmacy records establishing when voxelotor was taken and for how long are the threshold evidence.
Temporal relationship
How closely the injury followed the start of treatment, and whether it resolved on discontinuation.
Baseline disease severity
Sickle cell disease itself causes many of the alleged injuries, and this will be the central defence argument.
Age and dependants
Younger claimants and wrongful death claims with surviving dependants generally value higher.
Economic loss
Hospital costs, ongoing care, lost earnings and future care needs.
Evidence That Can Support a Oxbryta Claim
These claims are built on the prescription record and the haematology file, both of which will already exist for anyone treated for sickle cell disease.
Pharmacy Records
Prescription fills for voxelotor, with dates, dosage and duration.
Pharmacies can usually retrieve several years of dispensing history.Haematology Records
The treating specialist’s notes covering the period before, during and after voxelotor treatment.
Requested from the sickle cell clinic or haematology practice.Hospital Records
Admissions for stroke, acute chest syndrome, organ failure or crises, with the discharge summaries.
Requested from each admitting hospital.Baseline Disease History
Records establishing the pattern of crises and complications before voxelotor was started.
Essential, because the defence will attribute the injury to the underlying disease.Imaging and Laboratory Results
Scans and results documenting stroke, organ damage or necrosis.
Held by the treating hospital radiology and pathology departments.Damages Documentation
Medical bills, insurance statements, lost earnings and future care costs.
Assembled from providers, insurers and employers.Where Oxbryta Litigation Stands in 2026
This is an early-stage litigation. The withdrawal is documented and undisputed; almost everything else remains to be established.
At least one case is proceeding in the Northern District of California before Judge Trina L. Thompson. If filings increase substantially, the Judicial Panel on Multidistrict Litigation could consolidate them, which would change the timetable considerably.
Oxbryta Lawsuit Filing Deadlines
Limitation periods for pharmaceutical injury claims vary by state and generally run from the date of injury, or from the point at which the connection between the injury and the drug could reasonably have been discovered. For many claimants that discovery point is the September 2024 withdrawal announcement.
Wrongful death claims run on a separate and usually shorter timetable measured from the date of death.
Because the withdrawal is now nearly two years old, deadlines in shorter-limitation states may be closer than claimants expect. This is the litigation on this site where waiting carries the most immediate risk.
Oxbryta Lawsuit, Settlement & Related Claim Resources
Why the Estimate Is Not the Cheque
Any figure this calculator produces, and any figure quoted in a news headline, is a gross number. Several deductions sit between a gross allocation and the money that reaches a claimant, and they are the same in every mass tort.
1. Gross allocation
What the claim is valued at, before anything is taken out.
2. Attorney fees and costs
The contingency fee plus case expenses, set out in the retainer agreement you sign at the start.
3. Liens and reimbursements
Health insurers and Medicaid are repaid for hospital admissions, transfusions and ongoing care they funded.
4. Net to claimant
What remains after fees, costs and lien resolution — and what actually arrives.
Lien resolution is usually the step that takes longest. Health insurers, and in many cases Medicare or Medicaid, have a right to be reimbursed out of a settlement for treatment they already paid for. Those amounts can frequently be reduced through a formal resolution process, but the process adds time — often months between an agreed figure and a distributed payment.
None of this is a reason not to bring a claim. It is a reason to read every Oxbryta figure you encounter as a gross number rather than a net one, and to ask about the fee structure and likely lien exposure early rather than late.
Oxbryta Settlement Calculator FAQ
How does the Oxbryta settlement calculator work?
It organises prescription history, the injury alleged, treatment and damages into an educational summary. Because no settlement matrix exists, it cannot predict a payout.
What is the average Oxbryta settlement?
There is none. As of August 2026 there have been no trials, no verdicts and no publicly announced settlements in the Oxbryta litigation.
Why was Oxbryta withdrawn?
Pfizer withdrew it worldwide on 26 September 2024, citing clinical trial data showing more deaths among patients taking the drug than those on placebo, and higher rates of vaso-occlusive crises.
Is there an Oxbryta MDL?
Not as of August 2026. Cases have been filed individually across several states. The JPML could consolidate them if filings increase substantially.
My injury could have been caused by sickle cell disease itself. Does that end my claim?
Not automatically, but it is the central issue. Records establishing your pattern of crises and complications before voxelotor was started are what allow that argument to be addressed rather than assumed.
Does the calculator submit a claim?
No. It produces an educational summary and, if you choose, passes your details for a free case review. It does not file anything and creates no attorney-client relationship.
Request a Free Oxbryta Case Review
If you or a family member took Oxbryta for sickle cell disease and suffered a stroke, organ failure, acute chest syndrome or death, use the calculator to organise the records or request a confidential review.
Sources and Further Reading
FDA — Oxbryta (voxelotor) Withdrawal
The federal notice covering the September 2024 worldwide market withdrawal and the safety data behind it.
View the FDA noticePfizer — Voxelotor Statement
The company statement on the voluntary worldwide withdrawal.
View Pfizer newsU.S. District Court, Northern District of California
A court where individual Oxbryta cases are proceeding.
View the courtNIH — Sickle Cell Disease
Clinical background on sickle cell disease and its complications.
View the NIH pageJPML — Pending MDL Dockets
The panel that would consolidate Oxbryta cases if filings warrant it. No Oxbryta MDL exists as of August 2026.
View the JPML report
